[ad_1]
An important step in the search for the corona vaccine: According to a press release, Moderna has completed the third phase of the clinical study. It is the first pharmaceutical company to take this step.
After a two-month safety waiting period has been completed, Moderna wants to apply for special permission from the US health authorities to bring the vaccine to market. “This is an important milestone for us,” says Stéphane Bancel., Executive Director von Modern.
MRNA technology has potential
The third phase of the clinical study consists of testing the vaccine in a large number of subjects. About 30,000 people participated in the Moderna study and 25,650 people have already received the second dose of the vaccine. Moderna decided to develop a vaccine based on mRNA technology.
The American pharmaceutical company Moderna is the parent company of the Swiss pharmaceutical company Lonza. At Visp VS, this is already building a production line for the potential vaccine.
Meanwhile, two of the competing Pharama companies had to discontinue the third phase of the clinical study. AstraZeneca and Johnson & Johnson had intermittent issues with subjects. AstraZeneca has restarted the study. (lui)
